Strong Revenue and Prescription Growth Highlight Momentum Across Key Brands
Axsome Therapeutics delivered a robust third quarter for 2025, marked by total net product revenue of $171 million, representing 63% growth over the same period last year and 14% sequential growth. The company’s growth was driven primarily by AUVELITY and SUNOSI, its lead products in the major depressive disorder and sleep disorder spaces, respectively, as well as early traction from its newest launch, SYMBRAVO for migraine treatment.
Prescription Volume and Market Coverage Expand for Lead Products
AUVELITY prescriptions climbed to approximately 209,000, up 46% year-over-year and 9% sequentially, with payer coverage now reaching around 85% of all insured lives in the U.S. (75% commercial, 100% government). Meanwhile, SUNOSI prescriptions rose 12% compared to the previous year, reaching about 53,000, supported by an 83% overall coverage rate and nearly full coverage in commercial channels. For SYMBRAVO, the company reported about 5,000 prescriptions in its first full quarter on the market and achieved formulary contracts with two of the three largest group purchasing organizations, laying groundwork for further expansion.
| Product | 3Q25 Sales (in millions) | Y/Y Growth (%) | Prescriptions (Q3 2025) | Payer Coverage (%) |
|---|---|---|---|---|
| AUVELITY | $136.10 | 69 | 209,000 | 85 |
| SUNOSI | $32.80 | 35 | 53,000 | 83 |
| SYMBRAVO | $2.10 | N/A (New Launch) | 5,000 | 52 |
Pipeline Advances Support Growth Narrative
Axsome’s research pipeline remains active, highlighted by the recent sNDA submission to the FDA for AXS-05 in Alzheimer’s disease agitation, addressing a significant unmet need. Late-stage trials for multiple candidates, including solriamfetol in pediatric ADHD, major depressive disorder with excessive daytime sleepiness, binge eating disorder, and shift work disorder, are planned or ongoing with top-line results from two studies anticipated in 2026. The company also aims to submit an NDA for AXS-12 in narcolepsy before year-end and is advancing AXS-14 for fibromyalgia with Phase 3 trials set for the fourth quarter.
Loss Narrows Amid Investments in Commercial Expansion and R&D
While Axsome posted a net loss of $47.23 million (or $0.94 per share) for the quarter—improving from $64.60 million (or $1.34 per share) a year earlier—the results reflect higher spending on commercial activities for AUVELITY and the launch of SYMBRAVO, as well as ongoing R&D. Total SG&A expenses reached $150.24 million (vs. $95.56 million last year), while R&D spending fell as late-stage trials wrapped up. Importantly, cash and cash equivalents rose to $325.27 million, with the company projecting that it is well funded to reach cash flow positivity under the current operating plan.
| Key Financials (in millions) | Q3 2025 | Q3 2024 |
|---|---|---|
| Net Product Revenue | $171.00 | $104.80 |
| SG&A Expense | $150.24 | $95.56 |
| R&D Expense | $40.16 | $45.39 |
| Net Loss | $(47.23) | $(64.60) |
| Cash & Cash Equivalents | $325.27 | $315.35* |
*December 31, 2024
Key Takeaway: Positioned for Continued Growth With Eyes on Late-Stage Milestones
Axsome’s quarter paints the picture of a company scaling fast—with prescriptions, payer access, and revenue growing solidly. With multiple pivotal trial readouts, an imminent NDA, and broader insurance coverage secured for key therapies, the company is working to close the gap between robust top-line growth and bottom-line profitability. Investors and stakeholders may want to track the company’s cash position, milestone announcements (particularly FDA decisions and trial data), and further updates on coverage for AUVELITY and SYMBRAVO as indicators of long-term trajectory.
Contact Information:
If you have feedback or concerns about the content, please feel free to reach out to us via email at support@marketchameleon.com.
About the Publisher - Marketchameleon.com:
Marketchameleon is a comprehensive financial research and analysis website specializing in stock and options markets. We leverage extensive data, models, and analytics to provide valuable insights into these markets. Our primary goal is to assist traders in identifying potential market developments and assessing potential risks and rewards.
NOTE: Stock and option trading involves risk that may not be suitable for all investors. Examples contained within this report are simulated and may have limitations. Average returns and occurrences are calculated from snapshots of market mid-point prices and were not actually executed, so they do not reflect actual trades, fees, or execution costs. This report is for informational purposes only, and is not intended to be a recommendation to buy or sell any security. Neither Market Chameleon nor any other party makes warranties regarding results from its usage. Past performance does not guarantee future results. Please consult a financial advisor before executing any trades. You can read more about option risks and characteristics at theocc.com.
The information is provided for informational purposes only and should not be construed as investment advice. All stock price information is provided and transmitted as received from independent third-party data sources. The Information should only be used as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments and trading strategies. The Company does not guarantee the accuracy, completeness or timeliness of the Information.
Disclosure: This article was generated with the assistance of AI